SCHEMBL16371764

SCHEMBL16371764

O=C(NC1=C(c2ccc(Cl)cc2)CC1)c1ccccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.46
▸ P2RX7 Q99572 1/20 0.46
▸ GRM5 P41594 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ KCNK3 O14649 1/20 0.44
▸ KCNK9 Q9NPC2 1/20 0.44
▸ PTPRC P08575 1/20 0.42
▸ ANO1 Q5XXA6 1/20 0.42
▸ SCD O00767 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16372428 0.83 KDM4E (0.51) GAALMNAKDM4EGRM5PTGS1
SCHEMBL16485993 0.78 RECQL (0.43) GAALMNAKDM4EGRM5PTGS1
SCHEMBL16512729 0.78 GRM4 (0.45) GAALMNAKDM4EPTGS1KCNK3
SCHEMBL16486751 0.78 LMNA (0.48) GAALMNAP2RX7PTGS1KCNK3
SCHEMBL13477981 0.77 TDP1 (0.62) GAALMNAKDM4EGRM5PTGS1
SCHEMBL16372308 0.76 LMNA (0.59) GAALMNAPTGS1KCNK3KCNK9
SCHEMBL16371758 0.76 LMNA (0.55) GAALMNAKDM4EPTGS1KCNK3
SCHEMBL16392354 0.76 PTPRC (0.48) GAALMNAP2RX7PTGS1KCNK3
SCHEMBL16372385 0.76 LMNA (0.46) GAALMNAGRM5PTGS1KCNK3
SCHEMBL16513000 0.75 PTGES (0.46) GAALMNAKDM4EPTGS1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
EP-3019476-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES Syngenta Participations AG (CH) 2016-05-18 — — EP disclosed
WO-2015003951-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-15 — — WO disclosed
WO-2015003951-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS GAA 2228/4885LMNA 3548/4885KDM4E 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback